RESUMO
Clinically significant responses after withdrawal of flutamide in patients with hormone-refractory prostate cancer (HRPC) are well documented. Failure to recognize this syndrome of response results in potential morbidity due to salvage therapy, confusion in interpretation of disease state, and introduction of a possible source of error in clinical trials. In this case report, we describe a patient with HRPC whose prostate-specific antigen levels decreased substantially in response to withdrawal of megestrol acetate. Such a response should be considered when megestrol acetate is used in the treatment of HRPC.
Assuntos
Antineoplásicos Hormonais/administração & dosagem , Acetato de Megestrol/administração & dosagem , Antígeno Prostático Específico/sangue , Neoplasias da Próstata/tratamento farmacológico , Neoplasias da Próstata/imunologia , Humanos , Masculino , Pessoa de Meia-IdadeAssuntos
Anormalidades Induzidas por Medicamentos/etiologia , Anormalidades Múltiplas/etiologia , Antineoplásicos/efeitos adversos , Carcinoma Adenoide Cístico/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Complicações Neoplásicas na Gravidez/tratamento farmacológico , Neoplasias da Glândula Submandibular/tratamento farmacológico , Adulto , Carcinoma Adenoide Cístico/secundário , Feminino , Humanos , Recém-Nascido , Recém-Nascido Prematuro , Neoplasias Pulmonares/secundário , Gravidez , Primeiro Trimestre da Gravidez , Efeitos Tardios da Exposição Pré-Natal , Translocação GenéticaRESUMO
Warfarin is one of the most commonly used oral anticoagulants. Many medications have been shown to influence the prothrombin time in patients treated with warfarin by various mechanisms. We observed a major bleeding episode that resulted from a probable interaction between levamisole (Ergamisol), 5-fluorouracil, and warfarin. It is conceivable that many patients who are predisposed to thromboembolism because of cancer and surgery will be taking this combination of medications.
